Skip to main content
Top
Published in: BMC Infectious Diseases 1/2019

Open Access 01-12-2019 | Isoniazid | Research article

The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis

Authors: Demeke Geremew, Aklilu Endalamaw, Markos Negash, Setegn Eshetie, Belay Tessema

Published in: BMC Infectious Diseases | Issue 1/2019

Login to get access

Abstract

Background

Tuberculosis (TB) and HIV makeup a deadly synergy of infectious disease, and the combined effect is apparent in resource limited countries like Ethiopia. Previous studies have demonstrated inconsistent results about the protective effect of isoniazid preventive therapy (IPT) on active TB incidence among HIV positive patients receiving ART. Therefore, the aim of this meta-analysis was, first, to determine the protective effect of IPT on active tuberculosis incidence, and second, to assess the pooled incidence of active TB among HIV positive patients taking ART with and without IPT intervention in Ethiopia.

Methods

PubMed, Google scholar and Cochran library databases were searched from April 1 to 30, 2018. Two independent authors explored and assessed studies for eligibility, and extracted data based on predefined criteria. Studies that reported TB incidence among HIV positive patients taking ART in Ethiopia with and without IPT concomitant intervention, and with a clear stratified data on the incidence of TB based on the duration of IPT intervention were selected. A random effects model was used to estimate risk ratios and the pooled incident TB with the respective 95% confidence intervals.

Results

We identified 7 suitable studies in this analysis. Accordingly, IPT reduced the risk of TB incidence by 74%, risk ratio (RR) 0.26 (95% CI; 0.16–0.43%), compared to no IPT group. Moreover, IPT for 12 months reduced incident TB by 91% (RR: 0.09, 95% CI: 0.04 to 0.21), whereas 6 months IPT averted TB incidence by 63% (RR: 0.37, 95% CI: 0.26 to 0.52). The overall pooled incident TB among HIV infected patients receiving ART was 10.30% (95% CI; 7.57–13.02%). Specifically, incident TB among study cohorts with and without IPT was 3.79% (95% CI; 2.03–5.55%) and 16.32% (95% CI; 11.57–21.06%) respectively.

Conclusion

IPT reduced the risk of incident TB among HIV positive patients receiving ART in Ethiopian settings. Moreover, the duration of IPT intervention has effect on its protective role. Thus, scaling up the isoniazid preventive therapy program and its strict compliance is necessary to avert HIV fueled tuberculosis.

Study protocol registration

CRD42018090804.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sulis G, Roggi A, Matteelli A, Raviglione MC. Tuberculosis: epidemiology and control. Mediterr J Hematol Infect Dis. 2014;6(1). Sulis G, Roggi A, Matteelli A, Raviglione MC. Tuberculosis: epidemiology and control. Mediterr J Hematol Infect Dis. 2014;6(1).
3.
go back to reference Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber Lung Dis. 1992;73(6):311–21.CrossRef Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber Lung Dis. 1992;73(6):311–21.CrossRef
4.
go back to reference Swaminathan S, Padmapriyadarsini C, Narendran G. HIV-associated tuberculosis: clinical update. Clin Infect Dis. 2010;50(10):1377–86.CrossRef Swaminathan S, Padmapriyadarsini C, Narendran G. HIV-associated tuberculosis: clinical update. Clin Infect Dis. 2010;50(10):1377–86.CrossRef
5.
go back to reference WHO: Joint HIV and TB Department Meeting. Report from WHO’s Three I’s Meeting: intensified case finding (ICF), isoniazid preventive therapy (IPT) and TB infection control (IC) for people living with HIV. Geneva: WHO; 2008. WHO: Joint HIV and TB Department Meeting. Report from WHO’s Three I’s Meeting: intensified case finding (ICF), isoniazid preventive therapy (IPT) and TB infection control (IC) for people living with HIV. Geneva: WHO; 2008.
6.
go back to reference Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, Wilkinson KA, Goliath R, Mathee S, Goemaere E. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384(9944):682–90.CrossRef Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, Wilkinson KA, Goliath R, Mathee S, Goemaere E. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384(9944):682–90.CrossRef
7.
go back to reference Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (London, England). 2007;21(11):1441.CrossRef Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (London, England). 2007;21(11):1441.CrossRef
8.
go back to reference FMOH. Implementation Guideline for TB/HIV Collaborative Activities in Ethiopia. Addis Ababa: Federal Ministry of Health; 2008. FMOH. Implementation Guideline for TB/HIV Collaborative Activities in Ethiopia. Addis Ababa: Federal Ministry of Health; 2008.
9.
go back to reference Mindachew M, Deribew A, Memiah P, Biadgilign S. Perceived barriers to the implementation of isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J. 2014;(1):17. Mindachew M, Deribew A, Memiah P, Biadgilign S. Perceived barriers to the implementation of isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J. 2014;(1):17.
10.
go back to reference Teklay G, Teklu T, Legesse B, Tedla K, Klinkenberg E. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health. 2016;16(1):840.CrossRef Teklay G, Teklu T, Legesse B, Tedla K, Klinkenberg E. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health. 2016;16(1):840.CrossRef
11.
go back to reference FMOH. National guidelines for comprehensive HIV prevention, care and treatment. Addis Ababa: Federal Ministry of Health; 2017. FMOH. National guidelines for comprehensive HIV prevention, care and treatment. Addis Ababa: Federal Ministry of Health; 2017.
12.
go back to reference Balcha TT, Jeppsson A. Outcomes of antiretroviral treatment: a comparison between hospitals and health centers in Ethiopia. J Int Assoc Phys AIDS Care. 2010;9(5):318–24.CrossRef Balcha TT, Jeppsson A. Outcomes of antiretroviral treatment: a comparison between hospitals and health centers in Ethiopia. J Int Assoc Phys AIDS Care. 2010;9(5):318–24.CrossRef
13.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.CrossRef
15.
go back to reference Wells G, Shea B, Connell OD, J Peterson, V Welch, M Losos, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2008. http://wwwohrica/programs/clinical_ epidemiology/oxfordasp (accessed 14/06/2018). Wells G, Shea B, Connell OD, J Peterson, V Welch, M Losos, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2008. http://​wwwohrica/​programs/​clinical_​ epidemiology/oxfordasp (accessed 14/06/2018).
16.
go back to reference DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRef
17.
go back to reference Fazel S, Khosla V, Doll H, Geddes J. The prevalence of mental disorders among the homeless in western countries: systematic review and meta-regression analysis. PLoS Med. 2008;5(12):e225.CrossRef Fazel S, Khosla V, Doll H, Geddes J. The prevalence of mental disorders among the homeless in western countries: systematic review and meta-regression analysis. PLoS Med. 2008;5(12):e225.CrossRef
18.
go back to reference Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974–8.CrossRef Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974–8.CrossRef
19.
go back to reference Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193.CrossRef Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193.CrossRef
20.
go back to reference Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323(7304):101.CrossRef Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323(7304):101.CrossRef
21.
go back to reference Abossie A, Yohanes T. Assessment of isoniazid preventive therapy in the reduction of tuberculosis among ART patients in arba Minch hospital, Ethiopia. Ther Clin Risk Manag. 2017;13:361.CrossRef Abossie A, Yohanes T. Assessment of isoniazid preventive therapy in the reduction of tuberculosis among ART patients in arba Minch hospital, Ethiopia. Ther Clin Risk Manag. 2017;13:361.CrossRef
22.
go back to reference Nigussie M. Incidence and factors predicting active TB occurrence among patients enrolled in ART, Zewditu hospital, Addis Ababa, retrospective cohort study; 2015. Nigussie M. Incidence and factors predicting active TB occurrence among patients enrolled in ART, Zewditu hospital, Addis Ababa, retrospective cohort study; 2015.
23.
go back to reference Edessa D, Woldeyes T, Shibeshi W. Comparison of effects of isoniazid plus ART and ART only regimen on the incidence of tuberculosis and HIV progression in HIV positive patients: a retrospective cohort study at two hospitals in Addis Ababa, Ethiopia. Int J Basic Clin Pharmacol. 2014;3(1):54–62.CrossRef Edessa D, Woldeyes T, Shibeshi W. Comparison of effects of isoniazid plus ART and ART only regimen on the incidence of tuberculosis and HIV progression in HIV positive patients: a retrospective cohort study at two hospitals in Addis Ababa, Ethiopia. Int J Basic Clin Pharmacol. 2014;3(1):54–62.CrossRef
24.
go back to reference Yirdaw KD, Jerene D, Gashu Z, Edginton M, Kumar AM, Letamo Y, Feleke B, Teklu AM, Zewdu S, Weiss B. Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia. PLoS One. 2014;9(8):e104557.CrossRef Yirdaw KD, Jerene D, Gashu Z, Edginton M, Kumar AM, Letamo Y, Feleke B, Teklu AM, Zewdu S, Weiss B. Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia. PLoS One. 2014;9(8):e104557.CrossRef
25.
go back to reference Alemu YM, Andargie G, Gebeye E. High incidence of tuberculosis in the absence of isoniazid and Cotrimoxazole preventive therapy in children living with HIV in northern Ethiopia: a retrospective follow-up study. PLoS One. 2016;11(4):e0152941.CrossRef Alemu YM, Andargie G, Gebeye E. High incidence of tuberculosis in the absence of isoniazid and Cotrimoxazole preventive therapy in children living with HIV in northern Ethiopia: a retrospective follow-up study. PLoS One. 2016;11(4):e0152941.CrossRef
26.
go back to reference Semu M, Fenta TG, Medhin G, Assefa D. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study. BMC Infect Dis. 2017;17(1):5.CrossRef Semu M, Fenta TG, Medhin G, Assefa D. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study. BMC Infect Dis. 2017;17(1):5.CrossRef
27.
go back to reference Ahmed A, Mekonnen D, Kindie M. Incidence and predictors of tuberculosis among adult people living with HIV/AIDS in Afar public health facilities, Northeast Ethiopia. AIDS. 2015;1:3–10. Ahmed A, Mekonnen D, Kindie M. Incidence and predictors of tuberculosis among adult people living with HIV/AIDS in Afar public health facilities, Northeast Ethiopia. AIDS. 2015;1:3–10.
28.
go back to reference FMOH. Guidelines for clinical and programmatic management of TB, Leprosy and TB/HIV in Ethiopia. Addis Ababa: Federal Ministry of Health; 2012. FMOH. Guidelines for clinical and programmatic management of TB, Leprosy and TB/HIV in Ethiopia. Addis Ababa: Federal Ministry of Health; 2012.
29.
go back to reference WHO. Implementing the WHO Stop TB Strategy: a handbook for national tuberculosis control programmes. Geneva: WHO; 2008. WHO. Implementing the WHO Stop TB Strategy: a handbook for national tuberculosis control programmes. Geneva: WHO; 2008.
30.
31.
go back to reference Alvarez-Uria G, Pakam R, Midde M, Naik PK. Incidence and mortality of tuberculosis before and after initiation of antiretroviral therapy: an HIV cohort study in India. J Int AIDS Soc. 2014;17(1):19251.CrossRef Alvarez-Uria G, Pakam R, Midde M, Naik PK. Incidence and mortality of tuberculosis before and after initiation of antiretroviral therapy: an HIV cohort study in India. J Int AIDS Soc. 2014;17(1):19251.CrossRef
32.
go back to reference Enju L, Makubi A, Drain P, Spiegelman D, Sando D, Nan L, Chalamilla G, Sudfeld CR, Hertzmark E, Fawzi WW. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy in Tanzania. AIDS (London, England). 2015;29(11):1391.CrossRef Enju L, Makubi A, Drain P, Spiegelman D, Sando D, Nan L, Chalamilla G, Sudfeld CR, Hertzmark E, Fawzi WW. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy in Tanzania. AIDS (London, England). 2015;29(11):1391.CrossRef
33.
go back to reference Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359(9323):2059–64.CrossRef Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359(9323):2059–64.CrossRef
34.
go back to reference Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, Rabie H, Lombard CJ. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Bmj. 2007;334(7585):136.CrossRef Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, Rabie H, Lombard CJ. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Bmj. 2007;334(7585):136.CrossRef
35.
go back to reference Giri PA, Deshpande JD, Phalke DB. Prevalence of pulmonary tuberculosis among HIV positive patients attending antiretroviral therapy clinic. N Am J Med Sci. 2013;5(6):367.CrossRef Giri PA, Deshpande JD, Phalke DB. Prevalence of pulmonary tuberculosis among HIV positive patients attending antiretroviral therapy clinic. N Am J Med Sci. 2013;5(6):367.CrossRef
36.
go back to reference Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors and prevention strategies. J Acquir Immune Defic Syndr (1999). 2011;56(4):349.CrossRef Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors and prevention strategies. J Acquir Immune Defic Syndr (1999). 2011;56(4):349.CrossRef
37.
go back to reference Yadav D, Jha N, Pokharel P, Niraula S, Bhattacharya S, Nagesh S. Study on the prevalence of pulmonary tuberculosis among Hiv positive attending Hiv clinics in eastern Nepal. SAARC J Tuberc Lung Dis HIV/AIDS. 2011;8(1):1–8. Yadav D, Jha N, Pokharel P, Niraula S, Bhattacharya S, Nagesh S. Study on the prevalence of pulmonary tuberculosis among Hiv positive attending Hiv clinics in eastern Nepal. SAARC J Tuberc Lung Dis HIV/AIDS. 2011;8(1):1–8.
Metadata
Title
The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis
Authors
Demeke Geremew
Aklilu Endalamaw
Markos Negash
Setegn Eshetie
Belay Tessema
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2019
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-4031-2

Other articles of this Issue 1/2019

BMC Infectious Diseases 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.